Stryker: Strong Fundamentals and Growth Prospects Largely Priced In, Justifying a Hold Rating

Stryker, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD Cowen downgraded the rating on the stock to a Hold and gave it a $387.00 price target.

Josh Jennings has given his Hold rating due to a combination of factors that balance Stryker’s strong fundamentals with its current valuation. He highlights Stryker as a top-tier medical technology company with attractive end markets, disciplined leadership under CEO Kevin Lobo, and a track record of consistent high-single to low-double-digit organic revenue growth accompanied by improving margins. Jennings also notes that portfolio moves, such as recent acquisitions and divestitures, along with ongoing product launches, leave room for Stryker to continue delivering near double-digit growth and incremental margin expansion, supporting potential upside to both sales and earnings over the next few years.

At the same time, Jennings believes much of this strength is already embedded in the stock price. He points out that the shares trade at a premium multiple that, while slightly below their recent historical averages, still factors in sustained outperformance and the company’s pattern of beating and raising expectations. His $387 price target, based on a high-20s earnings multiple on 2026 estimates that are essentially in line with consensus, implies only modest further upside from current levels. As a result, with limited room for valuation expansion unless new, underappreciated growth drivers emerge, he concludes that a Hold rating is appropriate rather than a more aggressive stance.

Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year.